Researchers have developed an implantable device to detect and respond to opioid overdose.
In preclinical models, the subcutaneously implanted device was able to continuously monitor vital signs and delivered naloxone automatically and rapidly when it detected opioid overdose.
The opioid epidemic continues to have devastating effects, exacerbated by the increasing presence of fentanyl in illicit opioids.
Naloxone is an effective antidote, but it usually requires rapid administration from a bystander.
Now, researchers have developed an implantable device to detect and reverse opioid overdoses.
The device, which they call “iSOS,” continuously monitors heart and respiratory systems for signs of overdose and automatically delivers naloxone when necessary.
In preclinical studies, iSOS effectively detected and reversed opioid overdoses.
“Naloxone is life-saving but frequently may not be delivered in time,” said co-first author Peter Ray Chai, MD, MS, Department of Emergency Medicine at Brigham and Women’s Hospital.
“The iSOS device provides a highly innovative strategy to provide detection of opioid overdose, allowing for precise administration of naloxone at the moment it is needed, hopefully saving individuals from overdose and facilitating continued recovery from opioid use disorder.”
During overdoses, people generally lose consciousness, so having an automated delivery system for naloxone could save the lives of people who use opioids by themselves.
“In overdose cases where there is a bystander nearby, that individual can be rescued through either intramuscular or intranasal administration of naloxone, but you need that bystander.
“We wanted to find a way for this to be done in an autonomous fashion.” said corresponding author Giovanni Traverso, of the Department of Medicine at Brigham and Women’s Hospital and MIT.
To do away with the need for bystander intervention, the researchers wanted to design a “closed loop” system that could both detect opioid overdose and deliver the drug without outside guidance.
To enable autonomous detection, the team fitted the device with multiple sensors that continuously monitor the user’s respiratory rate, heart rate, body temperature, and blood oxygen saturation.
These sensors connect to an algorithm that is trained to recognise the signs of overdose by integrating the various cardiorespiratory signals.
When the device detects a suspected opioid overdose, it begins buzzing to alert the user and sends an alert to their phone which allows the user to cancel naloxone administration if they are not experiencing an overdose.
If it is not overridden, the device administers a shot of naloxone directly into the user’s tissue.
“Beyond the closed loop, the device can also serve as an early detection or warning system that can help alert others—whether it be loved ones, healthcare professionals or emergency services—to the side of the person so that they can help intervene as well,” said Traverso.
“To combat the high mortality associated with opioid overdoses, our fully implantable iSOS—with its continuous monitoring and rapid drug infusion capabilities—could serve as a pivotal next-generation antidote platform,” said co-first author Seungho Lee.
The prototype device measures 8 mm x 12 mm x 78 mm (larger than a contraceptive implant but smaller than a subcutaneous cardiac defibrillator).
It has a wirelessly rechargeable battery that can last up to 14 days, a refillable drug reservoir, and can be implanted subcutaneously via a minimally invasive procedure under local anaesthesia.
The team tested the device’s safety and efficacy in a large animal model, finding that the device effectively detected and reversed opioid overdoses in 24 out of 25 pigs.
The researchers note that the device could be particularly useful for individuals who have previously overdosed, since these individuals are more likely to overdose again.
They also say that having an implantable device may be more effective than a wearable device.
“The problem with wearables is that one has to wear them, and that in itself presents a potential challenge from an adherence perspective,” says Traverso.
“If the patient really wants to help protect themselves against overdose, an implantable or ingestible device could help support this sort of general vision.”
The researchers are now working to further optimize and miniaturise the device and intend to conduct additional preclinical trials before moving onto human testing.
They also plan to begin collecting data on end-user preferences to help guide their engineering efforts.
“Understanding the preferences of this patient population will be a critical part of our ongoing work to develop and mature this technology, said Traverso.
“This is only the first lab-based prototype, but even at this stage we’re seeing that this device has a lot of potential to help protect high-risk populations from what otherwise could be a lethal overdose.”
